Researchers have discovered a new metabolic vulnerability in a highly aggressive form of non-small cell lung cancer (NSCLC). These findings could pave the way for new treatments for patients with mutations in two key genes - KRAS and LKB1. Patients whose tumors contain both of these mutations, known as KL tumors, have poor outcomes and usually do not respond to immunotherapy.
from Latest Science News -- ScienceDaily https://ift.tt/2MtMp5U
via IFTTT
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment